WO2014117232A1 - Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal - Google Patents
Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal Download PDFInfo
- Publication number
- WO2014117232A1 WO2014117232A1 PCT/BR2013/000038 BR2013000038W WO2014117232A1 WO 2014117232 A1 WO2014117232 A1 WO 2014117232A1 BR 2013000038 W BR2013000038 W BR 2013000038W WO 2014117232 A1 WO2014117232 A1 WO 2014117232A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicinal
- foam
- syringe
- preparation
- medicinal preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention describes a foamed medicinal preparation for the sustained release of medicaments and the system for obtaining the medicinal preparation. More specifically it comprises a foamed medicinal preparation obtained from albumin and carbon dioxide for the purpose of carrying and releasing drugs by intravascular (arterial or venous), intracavitary injection through catheters or punctures, topical or even parenteral application, in order to reach target organs and prolong the contact time of the drug.
- foams The main clinical use of foams has been in sclerotherapy.
- a mixture of a substance that promotes sclerosing and air into the varicose veins is injected into the foam in order to block the diseased veins.
- sodium tetradecyl sulfate is the most widely used sclerosing agent in therapy, where a solution of this drug is mixed with ambient air and a foam is obtained whose stability is not yet satisfactory.
- a stable biocompatible foamed medicament preparation with the maintenance of its structure and viscosity for a longer period than the foams currently used in sclerotherapy techniques is such that the foamed medicament is It keeps in contact with its target for a longer time, aiding in therapeutic efficacy and reducing the distribution in other tissues, reducing side effects.
- It is an object of the invention a foamed medicinal preparation for the sustained release of medicaments comprising a solution of albumin and carbon dioxide providing a fully biocompatible foam.
- the object of the invention is a foamed medicinal preparation for the prolonged release of medicaments which provides longer residence time of the drugs in the target organ or tissue, promoting gradual and prolonged release, reducing withdrawal. these drugs from the site of action by the bloodstream and their eventual transport to other organs and tissues, reducing the toxicity and side effects of drugs such as chemotherapeutic drugs.
- Figure 1 shows the system for preparing the foam formulation, with two syringes (A and B) of varying volume with luerlock and a two-way tap.
- Figure 2 shows the assembled system, showing the interconnected syringes each other via the two-way tap, so that the syringe (A) contains albumin and the syringe (B) contains the carbon dioxide (C0 2) and (s) drug (s) or substances to be incorporated into the foam.
- FIGS 3 and 3A show the process of T albumin mixture with carbon dioxide, wherein the content of needles (A and B) transits through the two-way tap.
- Figure 4 shows the disconnection of one of the syringes of the 2-way tap and Figure 4A shows the syringe containing the mixture of albumin and carbon dioxide under conditions of use.
- the medicinal preparation in the form of foam for the sustained release of drugs, object of the present invention comprises human albumin, preferably in a concentration of 20% and carbon dioxide (C0 2).
- the ratio of mixture of carbon dioxide (C0 2) and the albumin solution is 3: 1 v / v, resulting in a foam with better stability and higher viscosity.
- the system for obtaining the foamed medicinal preparation for the sustained release of medicaments comprises a first syringe (A) with human albumin and a second syringe (B) with carbon dioxide.
- Syringes (A and B) are connected at the distal end (20) to a two-way tap (30) to prevent ambient air from entering, the second syringe (B) being removably attached to one of the ports ( 31) from the tap (10) and the first syringe (A) removably attached to the second way (32) of the tap (10).
- one or more medicaments are added to the carbon dioxide-containing syringe (B) at specific dosages according to the treatment. ⁇
- one or more drugs are combined in the albumin-containing syringe (A) if strictly necessary for specific reasons of storage incompatibility with carbon dioxide, or for better stability of the substance when dissolved in albumin.
- the tap (10) is opened promote the mixing of albumin with carbon dioxide.
- the plungers of both syringes (A and B) are pressed to promote uninterrupted flow between the syringes, generating the foam.
- the non-soldered two-way tap syringe (10) is released for use in the application of the medicament composition.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/BR2013/000038 WO2014117232A1 (pt) | 2013-02-04 | 2013-02-04 | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/BR2013/000038 WO2014117232A1 (pt) | 2013-02-04 | 2013-02-04 | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014117232A1 true WO2014117232A1 (pt) | 2014-08-07 |
Family
ID=51261328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2013/000038 WO2014117232A1 (pt) | 2013-02-04 | 2013-02-04 | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014117232A1 (pt) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033474A1 (en) * | 1996-03-12 | 1997-09-18 | Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
WO1998000172A2 (en) * | 1996-06-28 | 1998-01-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
WO1998018500A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
WO1999013919A1 (en) * | 1997-09-17 | 1999-03-25 | Imarx Pharmaceutical Corp. | Novel targeted contrast agents for diagnostic and therapeutic use |
WO2000002588A1 (en) * | 1998-07-13 | 2000-01-20 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
US6245747B1 (en) * | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
WO2006127953A2 (en) * | 2005-05-23 | 2006-11-30 | University Of Utah Research Foundation | Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents |
WO2009117688A2 (en) * | 2008-03-21 | 2009-09-24 | The Board Of Trustees Of The University Of Arkansas | Methods for producing microbubbles |
-
2013
- 2013-02-04 WO PCT/BR2013/000038 patent/WO2014117232A1/pt active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033474A1 (en) * | 1996-03-12 | 1997-09-18 | Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
US6245747B1 (en) * | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
WO1998000172A2 (en) * | 1996-06-28 | 1998-01-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
WO1998018500A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
WO1999013919A1 (en) * | 1997-09-17 | 1999-03-25 | Imarx Pharmaceutical Corp. | Novel targeted contrast agents for diagnostic and therapeutic use |
WO2000002588A1 (en) * | 1998-07-13 | 2000-01-20 | The Board Of Regents Of The University Of Nebraska | Targeted site specific drug delivery compositions and method of use |
WO2006127953A2 (en) * | 2005-05-23 | 2006-11-30 | University Of Utah Research Foundation | Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents |
WO2009117688A2 (en) * | 2008-03-21 | 2009-09-24 | The Board Of Trustees Of The University Of Arkansas | Methods for producing microbubbles |
Non-Patent Citations (3)
Title |
---|
KLIBANOV, A.L. ET AL.: "Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications", INVESTIGATIVE RADIOLOGY, vol. 41, no. 3, 2006, pages 354 - 362 * |
MATSUDA, Y. ET AL.: "Properties of gas (C02) microbubbles made by hand agitation and it's contrast enhancing effect", NIHON RINSHO, vol. 56, no. 4, 1998, pages 866 - 870 * |
RIZAEV, M.N. ET AL.: "Contrast echography of uterine tumors using albumin-carbon dioxide-foam", RADIOL. DIAGN. (BERL, vol. 31, no. 1, 1990, pages 81 - 85 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11696890B2 (en) | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity | |
ES2346955T3 (es) | Espuma inyectable y aplicaciones farmaceuticas novedosas de la misma. | |
CN104394848B (zh) | 小分子药物的用于胃肠外注射的稳定制剂 | |
Disa et al. | Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration | |
AU2006239313A1 (en) | Methods and compositions for treating pain | |
CN104427977A (zh) | 局部麻醉剂的储库制剂及其制备方法 | |
CN103040741B (zh) | 溶致液晶的前体混悬液及其制备方法 | |
van Hoogevest et al. | The use of phospholipids to make pharmaceutical form line extensions | |
CN103800278A (zh) | 透明质酸联合聚桂醇在制备治疗静脉畸形泡沫硬化药物中的应用 | |
ES2284695T3 (es) | Medicamento analgesico. | |
EP3821920A1 (en) | Combination for endoscopic surgery | |
WO2014117232A1 (pt) | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal | |
US11241412B2 (en) | Tumescent infiltration drug delivery of cannabinoids | |
CN110870858A (zh) | 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用 | |
CN105030682B (zh) | 一种纳米微粒胶体及其制备方法与用途 | |
CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
CN107648598B (zh) | 一种用于治疗急性缺血性脑卒中的药物组合物 | |
CN103735552B (zh) | 替格瑞洛和西洛他唑的药物组合物及其制备方法和应用 | |
CN106924174A (zh) | 一种关节腔注射用阿普斯特凝胶剂及其制备方法 | |
CN104257683A (zh) | 聚桂醇在制备治疗舌下腺囊肿的药物中的应用 | |
CN101559037B (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
Kähler et al. | Current recommendations for prevention and therapy of extravasation reactions in dermato‐oncology | |
Anami et al. | Factors associated with phlebitis and venous pain due to intravenous injection of epirubicin hydrochloride | |
CN102552916B (zh) | 水杨酸钠的新用途 | |
CN103432074B (zh) | 吡喹酮乳剂注射液及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13873484 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015016790 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13873484 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112015016790 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150714 |